Pain and Poppies: The Good, the Bad, and the Ugly of Opioid AnalgesicsDistinct Subpopulations of Nucleus Accumbens Dynorphin Neurons Drive Aversion and RewardCRH Engagement of the Locus Coeruleus Noradrenergic System Mediates Stress-Induced Anxiety.Dynorphin Controls the Gain of an Amygdalar Anxiety CircuitWireless Optofluidic Systems for Programmable In Vivo Pharmacology and OptogeneticsA Trigger for Opioid Misuse: Chronic Pain and Stress Dysregulate the Mesolimbic Pathway and Kappa Opioid SystemArchitectural Representation of Valence in the Limbic System.Fabrication and application of flexible, multimodal light-emitting devices for wireless optogeneticsOptodynamic simulation of β-adrenergic receptor signalling.Stretchable multichannel antennas in soft wireless optoelectronic implants for optogeneticsMolecular mechanisms of opioid receptor-dependent signaling and behavior.Chemogenetic and Optogenetic Activation of Gαs Signaling in the Basolateral Amygdala Induces Acute and Social Anxiety-Like StatesExposure to chronic mild stress prevents kappa opioid-mediated reinstatement of cocaine and nicotine place preferenceInjectable, cellular-scale optoelectronics with applications for wireless optogenetics.Locus coeruleus kappa-opioid receptors modulate reinstatement of cocaine place preference through a noradrenergic mechanismHippocampal long-term potentiation is disrupted during expression and extinction but is restored after reinstatement of morphine place preference.Spatiotemporal control of opioid signaling and behavior.Mouse strain differences in locomotor, sensitisation and rewarding effect of heroin; association with alterations in MOP-r activation and dopamine transporter binding.Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.Preparation and implementation of optofluidic neural probes for in vivo wireless pharmacology and optogenetics.Nicotine aversion is mediated by GABAergic interpeduncular nucleus inputs to laterodorsal tegmentum.
P50
Q26782928-61984002-8E90-4A97-80FB-BD9797319478Q27305210-D660E99E-47CA-473E-BBFB-061E4E58B3ABQ27305281-FEB2E01F-1BAB-40AE-BA27-015472F7FA27Q27319741-076F7333-E9A9-4315-8FC5-81EB7CA27122Q27322457-6FA73A98-EB05-4554-8F3A-9190CFA3843AQ28074686-A027FAE9-3321-47BE-84F7-08333A68D47BQ30355371-A6818ABB-8294-4F22-BD40-EB99804E3E47Q30577343-3BB961A6-86DE-4E36-938B-C4341F9FC581Q30666240-325629BA-07AB-40DA-BEFE-3E1248823E69Q30832387-7864A0B5-812D-4CB8-9A86-BC2E3218D5F3Q36974487-14C69BCF-3530-4887-A128-1615EB4598C1Q37006297-8C5C6E35-7281-48C0-83EC-5E29F4D43B4FQ37072200-07B57D3C-E814-4A86-8165-3555A83F8D9AQ37162596-2FF4A48D-00F0-42A1-822E-EC672DA5B91EQ37235834-E245008C-1483-450A-8767-1B2F34C4F392Q37410005-0C1AD05D-F501-4A56-B220-3B28B5E22792Q40980957-F2647A84-31ED-4D9B-B648-717ACAF5E557Q43102838-75C77000-CB63-4144-B5C6-B051AEB32E96Q45941093-D07BE070-4EC4-4312-9CE8-8480238CEF1EQ48050521-05C01491-1CAA-4A3E-ACEC-D41688CBC048Q55642075-69293E10-20F4-46F2-86B9-0B062F201632
P50
description
British neuroscientist and pharmacologist
@en
name
Ream Al-Hasani
@en
Ream Al-Hasani
@sl
type
label
Ream Al-Hasani
@en
Ream Al-Hasani
@sl
prefLabel
Ream Al-Hasani
@en
Ream Al-Hasani
@sl
P2002
reamalhasani